ClinicalTrials.gg
TerminatedNCT05131204ACCESS 2Updated Apr 8, 2025Results posted

Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

A Phase 3 interventional study of Cemdisiran and Eculizumab in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Regeneron Pharmaceuticals. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-08.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor decision not related to efficacy or safety.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal — none open to participants now, none under way, none of them phase 3. eculizumab · Hemoglobinuria, Paroxysmal.

Enrollment
18th of 18
3 · median 37
Started
2022
the only one that year
Phase 3
14 of 18
none open now
Registered
15th of 18
by date
Lead sponsor
1 of 18
Regeneron Pharmaceuticals

Among the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal, this one is the 18th largest by enrollment, is the only one that started in 2022, is one of 14 in phase 3, and was the 15th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

None of the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal is open now. The open studies under Hemoglobinuria, Paroxysmal, anywhere →

About eculizumab

eculizumab: first FDA approval 2007 (SOLIRIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal as a file.
02

Study summary

The primary objective of the study is:

To evaluate the effect of pozelimab and cemdisiran combination therapy on hemolysis, as assessed by lactate dehydrogenase (LDH), after 36 weeks of treatment, in patients with PNH who switch from eculizumab or ravulizumab therapy versus patients who continue their eculizumab or ravulizumab therapy

The secondary objectives of the study are to:

  • Evaluate the effect of pozelimab and cemdisiran combination treatment versus anti-C5 standard-of-care treatment (eculizumab or ravulizumab) on the following:

    • Transfusion requirements and transfusion parameters
    • Measures of hemolysis: LDH control, breakthrough hemolysis, and inhibition of CH50
    • Hemoglobin levels
    • Fatigue as assessed by Clinical Outcome Assessments (COAs)
    • Health-related quality of life (HRQoL) as assessed by COAs
    • Safety and tolerability
  • To assess the concentrations of total pozelimab and either total eculizumab or total ravulizumab in serum and total cemdisiran and total C5 protein in plasma
  • To assess the immunogenicity of pozelimab and cemdisiran
03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria

Keywords

  • PNH
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Diagnosis of PNH confirmed by a history of high-sensitivity flow cytometry from prior testing
  2. Treated with eculizumab or ravulizumab prior to screening visit as described in the protocol Note: Biosimilars are not permitted, unless approved by the Sponsor

Key Exclusion Criteria:

  1. Patients with a screening LDH >1.5 × who have not taken their C5 inhibitor within the labeled dose interval at the dose prior to the screening LDH assessment
  2. Receipt of an organ transplant, history of bone marrow transplantation or other hematologic transplant
  3. Body weight \< 40 kilograms at screening visit
  4. Any use of complement inhibitor therapy other than eculizumab or ravulizumab in the 26 weeks prior to the screening visit or planned use during the study with the exception of study treatments
  5. Not meeting meningococcal vaccination requirements for eculizumab or ravulizumab according to the current local prescribing information (where available) and at a minimum documentation of meningococcal vaccination within 5 years prior to screening visit.
  6. Any for receiving Neisseria meningitidis vaccination.
  7. Positive for , and/ or as described in the protocol
  8. History of cancer within the past 5 years, except for adequately treated basal cell skin cancer, squamous cell skin cancer, or in situ cervical cancer
  9. Participation in another interventional clinical study (except R3918-PNH-2021) or use of any experimental therapy within 30 days before screening visit or within 5 half-lives of that product, whichever is greater, with the exception of eculizumab or ravulizumab.
  10. Patients with functional or anatomic asplenia

Note: Other protocol-defined Inclusion/ Exclusion Criteria apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Pozelimab and Cemdisiran

    Randomized 1:1

    Drug: Cemdisiran · Drug: Eculizumab · Drug: Pozelimab · Drug: Ravulizumab

  • Experimental
    Anti-C5 standard-of-care

    Randomized 1:1

    Drug: Eculizumab · Drug: Ravulizumab

Interventions

  • Administered per protocol

    Also known as: ALN-CC5

  • Administered per protocol

    Also known as: Soliris

  • Administered per protocol

    Also known as: REGN3918

  • Administered per protocol

    Also known as: ALXN1210, Ultomiris

06

What researchers measure

Primary outcomes

  1. Percent Change in Lactate Dehydrogenase (LDH) From Baseline to Week 36

    Time frame: From baseline to week 36

Secondary outcomes

  1. Percentage of Participants With Transfusion Avoidance After Day 1 Through Week 36

    Participants who do not receive a red blood cell (RBC) transfusion as per protocol algorithm based on post baseline hemoglobin values

    Time frame: Day 1 through week 36

  2. Percentage of Participants With Transfusion Avoidance From Week 4 Through Week 36

    Participants who do not receive an RBC transfusion as per protocol algorithm based on post baseline hemoglobin values

    Time frame: Week 4 through week 36

  3. Percentage of Participants With Breakthrough Hemolysis After Day 1 Through Week 36

    Participants with an increase in LDH with concomitant signs or symptoms associated with hemolysis as described in the protocol

    Time frame: Day 1 through week 36

  4. Percentage of Participants With Breakthrough Hemolysis From Week 4 Through Week 36

    Participants with an increase in LDH with concomitant signs or symptoms associated with hemolysis as described in the protocol

    Time frame: Week 4 (day 29) through week 36

  5. Percentage of Participants With Hemoglobin Stabilization After Day 1 Through Week 36

    Participants who do not receive an RBC transfusion and have no decrease in hemoglobin level as defined in the protocol

    Time frame: Day 1 through week 36

  6. Percentage of Participants With Hemoglobin Stabilization From Week 4 Through Week 36

    Participants who do not receive an RBC transfusion and have no decrease in hemoglobin level as defined in the protocol

    Time frame: Week 4 (day 29) through week 36

  7. Percentage of Participants With Adequate Control of LDH From Week 8 Through Week 36

    Percentage of participants with adequate control of LDH as defined in the protocol

    Time frame: Week 8 (day 57) through week 36

  8. Percentage of Participants With Adequate Control of LDH After Day 1 Though Week 36

    Percentage of participants with adequate control of LDH as defined in the protocol

    Time frame: Day 1 through week 36

  9. Percentage of Participants Who Maintained Adequate Control of Hemolysis From Week 8 Through Week 36

    Percentage of participants with adequate control of LDH as defined in the protocol

    Time frame: Week 8 through week 36

  10. Percentage of Participants Who Maintained Adequate Control of Hemolysis After Day 1 Through Week 36

    Percentage of participants with adequate control of LDH as defined in the protocol

    Time frame: Day 1 through week 36

  11. Percentage of Participants With Normalization of LDH From Week 8 Through Week 36

    Percentage of participants with normalization of LDH as defined in the protocol

    Time frame: Week 8 (day 57) through week 36

  12. Percentage of Participants With Normalization of LDH After Day 1 Through Week 36

    Percentage of participants with normalization of LDH as defined in the protocol

    Time frame: Day 1 through week 36

  13. Change in Fatigue as Measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale From Baseline to Week 36

    The FACIT-Fatigue is a 13 item, self-administered clinical outcome assessment (COA) assessing an individual's level of fatigue during their usual daily activities over the past week. This questionnaire is part of the FACIT measurement system, a compilation of questions measuring health related quality of life (QoL) in patients with cancer and other chronic illnesses. The FACIT-Fatigue assesses the level of fatigue using a Likert scale ranging from 0 (not at all) to 4 (very much). Scores range from 0 to 52, with higher scores indicating greater fatigue.

    Time frame: From baseline to week 36

  14. Change in Physical Function (PF) Score on the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 Items (EORTC-QLQ-C30) From Baseline to Week 36

    EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale, with 1 as "not at all" and 4 as "very much."

    Time frame: From baseline to week 36

  15. Change in Global Health Status (GHS)/QoL Scale Score on the EORTC-QLQ-C30 From Baseline to Week 36

    EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea and vomiting, and pain), and 7 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, sleep and financial difficulties). Participants rate items on a 4-point scale, with 1 as "not at all" and 4 as "very much."

    Time frame: From baseline to week 36

  16. Rate of RBCs Transfused Per Protocol Algorithm After Day 1 Through Week 36

    Per protocol algorithm

    Time frame: Day 1 through week 36

  17. Rate of RBCs Transfused Per Protocol Algorithm From Week 4 Through Week 36

    Per protocol algorithm

    Time frame: Week 4 through week 36

  18. Number of Units of RBCs Transfused Per Protocol Algorithm After Day 1 Through Week 36

    Per protocol algorithm

    Time frame: Day 1 through week 36

  19. Number of Units of RBCs Transfused Per Protocol Algorithm From Week 4 Through Week 36

    Per protocol algorithm

    Time frame: Week 4 through week 36

  20. Change in Hemoglobin Levels From Baseline to Week 36

    Per protocol algorithm

    Time frame: From baseline to week 36

  21. Incidence of Treatment Emergent Serious Adverse Events (SAEs)

    Treatment period and safety follow up period

    Time frame: Up to week 29

  22. Incidence of Treatment-emergent Adverse Events (TEAEs) of Special Interest

    Treatment period and safety follow up period

    Time frame: Up to week 29

  23. Incidence of TEAEs Leading to Treatment Discontinuation

    Treatment period and safety follow up period

    Time frame: Up to week 29

  24. Change in Total CH50 From Baseline to Week 36

    Time frame: From baseline to week 36

  25. Percent Change in Total CH50 From Baseline to Week 36

    Time frame: From baseline to week 36

  26. Concentration of Total C5 in Plasma Through Week 62

    Treatment period and safety follow up period

    Time frame: Through week 62

  27. Concentrations of Total Pozelimab in Serum Through Week 62

    Treatment period and safety follow up period

    Time frame: Through week 62

  28. Concentrations of Total Cemdisiran in Plasma Through Week 32

    Treatment period

    Time frame: Through week 32

  29. Concentrations of Total Eculizumab in Serum Through Week 40

    Treatment period

    Time frame: Through week 40

  30. Concentrations of Total Ravulizumab in Plasma Through Week 44

    Treatment period

    Time frame: Through week 44

  31. Incidence of Treatment Emergent Anti-drug Antibodies (ADAs) to Pozelimab Through Week 62

    Treatment period and safety follow up period

    Time frame: Through week 62

  32. Incidence of Treatment Emergent ADAs to Cemdisiran Through Week 62

    Treatment period and safety follow up period

    Time frame: Through week 62

07

Results

Posted Sep 19, 2024
Limitations and caveats
20Dec2022 - Due to feasibility challenges related to enrollment and not due to efficacy or safety concerns, the sponsor terminated the study early and discontinued participant enrollment.

Participant flow

Participant flow — Overall Study
MilestonePozelimab and CemdisiranAnti-C5 Standard-of-care
Started21
Completed00
Not completed21
Withdrew: Sponsor request21

Outcome measures

PrimaryPercent Change in Lactate Dehydrogenase (LDH) From Baseline to Week 36
Time frame:
From baseline to week 36

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Transfusion Avoidance After Day 1 Through Week 36

Participants who do not receive a red blood cell (RBC) transfusion as per protocol algorithm based on post baseline hemoglobin values

Time frame:
Day 1 through week 36

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Transfusion Avoidance From Week 4 Through Week 36

Participants who do not receive an RBC transfusion as per protocol algorithm based on post baseline hemoglobin values

Time frame:
Week 4 through week 36

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Breakthrough Hemolysis After Day 1 Through Week 36

Participants with an increase in LDH with concomitant signs or symptoms associated with hemolysis as described in the protocol

Time frame:
Day 1 through week 36

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Breakthrough Hemolysis From Week 4 Through Week 36

Participants with an increase in LDH with concomitant signs or symptoms associated with hemolysis as described in the protocol

Time frame:
Week 4 (day 29) through week 36

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Hemoglobin Stabilization After Day 1 Through Week 36

Participants who do not receive an RBC transfusion and have no decrease in hemoglobin level as defined in the protocol

Time frame:
Day 1 through week 36

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Hemoglobin Stabilization From Week 4 Through Week 36

Participants who do not receive an RBC transfusion and have no decrease in hemoglobin level as defined in the protocol

Time frame:
Week 4 (day 29) through week 36

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Adequate Control of LDH From Week 8 Through Week 36

Percentage of participants with adequate control of LDH as defined in the protocol

Time frame:
Week 8 (day 57) through week 36

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Adequate Control of LDH After Day 1 Though Week 36

Percentage of participants with adequate control of LDH as defined in the protocol

Time frame:
Day 1 through week 36

No measurements were reported for this outcome.

SecondaryPercentage of Participants Who Maintained Adequate Control of Hemolysis From Week 8 Through Week 36

Percentage of participants with adequate control of LDH as defined in the protocol

Time frame:
Week 8 through week 36

No measurements were reported for this outcome.

SecondaryPercentage of Participants Who Maintained Adequate Control of Hemolysis After Day 1 Through Week 36

Percentage of participants with adequate control of LDH as defined in the protocol

Time frame:
Day 1 through week 36

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Normalization of LDH From Week 8 Through Week 36

Percentage of participants with normalization of LDH as defined in the protocol

Time frame:
Week 8 (day 57) through week 36

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Normalization of LDH After Day 1 Through Week 36

Percentage of participants with normalization of LDH as defined in the protocol

Time frame:
Day 1 through week 36

No measurements were reported for this outcome.

SecondaryChange in Fatigue as Measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale From Baseline to Week 36

The FACIT-Fatigue is a 13 item, self-administered clinical outcome assessment (COA) assessing an individual's level of fatigue during their usual daily activities over the past week. This questionnaire is part of the FACIT measurement system, a compilation of questions measuring health related quality of life (QoL) in patients with cancer and other chronic illnesses. The FACIT-Fatigue assesses the level of fatigue using a Likert scale ranging from 0 (not at all) to 4 (very much). Scores range from 0 to 52, with higher scores indicating greater fatigue.

Time frame:
From baseline to week 36

No measurements were reported for this outcome.

SecondaryChange in Physical Function (PF) Score on the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 Items (EORTC-QLQ-C30) From Baseline to Week 36

EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale, with 1 as "not at all" and 4 as "very much."

Time frame:
From baseline to week 36

No measurements were reported for this outcome.

SecondaryChange in Global Health Status (GHS)/QoL Scale Score on the EORTC-QLQ-C30 From Baseline to Week 36

EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea and vomiting, and pain), and 7 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, sleep and financial difficulties). Participants rate items on a 4-point scale, with 1 as "not at all" and 4 as "very much."

Time frame:
From baseline to week 36

No measurements were reported for this outcome.

SecondaryRate of RBCs Transfused Per Protocol Algorithm After Day 1 Through Week 36

Per protocol algorithm

Time frame:
Day 1 through week 36

No measurements were reported for this outcome.

SecondaryRate of RBCs Transfused Per Protocol Algorithm From Week 4 Through Week 36

Per protocol algorithm

Time frame:
Week 4 through week 36

No measurements were reported for this outcome.

SecondaryNumber of Units of RBCs Transfused Per Protocol Algorithm After Day 1 Through Week 36

Per protocol algorithm

Time frame:
Day 1 through week 36

No measurements were reported for this outcome.

SecondaryNumber of Units of RBCs Transfused Per Protocol Algorithm From Week 4 Through Week 36

Per protocol algorithm

Time frame:
Week 4 through week 36

No measurements were reported for this outcome.

SecondaryChange in Hemoglobin Levels From Baseline to Week 36

Per protocol algorithm

Time frame:
From baseline to week 36

No measurements were reported for this outcome.

SecondaryIncidence of Treatment Emergent Serious Adverse Events (SAEs)

Treatment period and safety follow up period

Time frame:
Up to week 29
Reported as:
Number · Events
Incidence of Treatment Emergent Serious Adverse Events (SAEs)
EventsPozelimab and CemdisiranAnti-C5 Standard-of-care
Incidence of Treatment Emergent Serious Adverse Events (SAEs)00
SecondaryIncidence of Treatment-emergent Adverse Events (TEAEs) of Special Interest

Treatment period and safety follow up period

Time frame:
Up to week 29
Reported as:
Number · Events
Incidence of Treatment-emergent Adverse Events (TEAEs) of Special Interest
EventsPozelimab and CemdisiranAnti-C5 Standard-of-care
Incidence of Treatment-emergent Adverse Events (TEAEs) of Special Interest10
SecondaryIncidence of TEAEs Leading to Treatment Discontinuation

Treatment period and safety follow up period

Time frame:
Up to week 29
Reported as:
Number · Events
Incidence of TEAEs Leading to Treatment Discontinuation
EventsPozelimab and CemdisiranAnti-C5 Standard-of-care
Incidence of TEAEs Leading to Treatment Discontinuation00
SecondaryChange in Total CH50 From Baseline to Week 36
Time frame:
From baseline to week 36

No measurements were reported for this outcome.

SecondaryPercent Change in Total CH50 From Baseline to Week 36
Time frame:
From baseline to week 36

No measurements were reported for this outcome.

SecondaryConcentration of Total C5 in Plasma Through Week 62

Treatment period and safety follow up period

Time frame:
Through week 62

No measurements were reported for this outcome.

SecondaryConcentrations of Total Pozelimab in Serum Through Week 62

Treatment period and safety follow up period

Time frame:
Through week 62

No measurements were reported for this outcome.

SecondaryConcentrations of Total Cemdisiran in Plasma Through Week 32

Treatment period

Time frame:
Through week 32

No measurements were reported for this outcome.

SecondaryConcentrations of Total Eculizumab in Serum Through Week 40

Treatment period

Time frame:
Through week 40

No measurements were reported for this outcome.

SecondaryConcentrations of Total Ravulizumab in Plasma Through Week 44

Treatment period

Time frame:
Through week 44

No measurements were reported for this outcome.

SecondaryIncidence of Treatment Emergent Anti-drug Antibodies (ADAs) to Pozelimab Through Week 62

Treatment period and safety follow up period

Time frame:
Through week 62

No measurements were reported for this outcome.

SecondaryIncidence of Treatment Emergent ADAs to Cemdisiran Through Week 62

Treatment period and safety follow up period

Time frame:
Through week 62

No measurements were reported for this outcome.

Adverse events

Collected over From first dose to week 29. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pozelimab and Cemdisiran0/2 (0%)0/2 (0%)2/2 (100%)
Anti-C5 Standard-of-care0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent other events
Most frequent other events
EventPozelimab and CemdisiranAnti-C5 Standard-of-care
Alanine aminotransferase increasedInvestigations0/21/1
EczemaSkin and subcutaneous tissue disorders0/21/1
Injection site rashGeneral disorders1/20/1
Blood glucose increasedInvestigations1/20/1

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Pozelimab and CemdisiranAnti-C5 Standard-of-careTotal
<=18 years000
Between 18 and 65 years213
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Pozelimab and CemdisiranAnti-C5 Standard-of-careTotal
Female101
Male112
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pozelimab and CemdisiranAnti-C5 Standard-of-careTotal
Hispanic or Latino000
Not Hispanic or Latino213
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pozelimab and CemdisiranAnti-C5 Standard-of-careTotal
White101
Black or African American000
Asian112
American Indian or Alaska Native000
Other000
Unknown000
Not Reported000
08

Study locations

1 site
  • Regeneron Research Facility
    Whittier, California 90603, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Jul 2023, 9 months.

Results were first posted in Sep 2024, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2021
First posted
Nov 23, 2021
StartActual
Oct 6, 2022
Primary completionActual
Jul 12, 2023
CompletionActual
Jul 12, 2023
Results first posted
Sep 19, 2024
Last update
Apr 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05131204
Responsible party
Sponsor
First posted
Nov 23, 2021
Start date
Oct 6, 2022
Primary completion
Jul 12, 2023
Completion
Jul 12, 2023
Results posted
Sep 19, 2024
Last update
Apr 8, 2025

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Eculizumab · Ravulizumab

Start the discussion